CPS 是 Combined Positive Score 的缩写,中文可以翻译为“综合阳性评分”。这是一种用于评估肿瘤样本中 PD-L1 表达水平的评分系统。PD-L1 (程序性死亡配体1) 是一种在某些类型的癌细胞上表达的蛋白质,它可以通过与免疫细胞上的 PD-1 受体结合来帮助肿瘤逃避人体免疫系统的攻击。 在不同的癌症类型和不同的研究...
Lebanon has one of the highest incidence of UC worldwide, yet no data exists regarding the expression of PD-L1 by Combined Positive Score (CPS) in advanced disease. Methods: We reviewed all patients treated at our institution for high grade UC, stage pT2 and above, between January 2017 ...
Immunotherapy targeting immune checkpoint proteins, such as programmed cell death ligand 1 (PD-L1), has shown impressive outcomes in many clinical trials but only 20%–40% of patients benefit from it. Utilizing Combined Positive Score (CPS) to evaluate PD-L1 expression in tumour biopsies to iden...
Background The Combined Positive Score (CPS) 1 algorithm includes tumor and immune cells for determination of Programed Death-Ligand 1 (PD-L1) protein expression in tumor tissues and has been analytically and clinically validated for use with PD-L1 IHC 22C3 pharmDx across multiple indications and...
PD-L1 status was assessed using immunohistochemical staining via the 22C3 assay (Dako North America, Carpinteria, CA, USA). PD-L1 expression was reported as a combined positive score (CPS), defined as the number of PD-L1-positive cells (tumor cells, lymphocytes, and macrophages) divided by...
We explored the associations of MPR with PD-L1 expression and microsatellite instability (MSI) status. In the combined positive score (CPS) < 1% subgroup (n = 45), the MPR rates were 27.3% and 17.4% in the CA-SAP and SAP groups, respectively (P = 0.331). Among the 54...
Based on our evaluation criteria of PD-L1 expression, the PD-L1-positive (score 2+ and 3+) rate was 15.5% (44/283) while the PD-L1-negative rate (score 0 and 1+) was 84.5% (239/283). MSI was observed in 7.8% (22/283) and EBV was detected in 8.1% (23/283). Table 1 ...
The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis. Cancer Immunology, Immunotherapy. 2024;73(7):125. doi:10.1007/s00262-024-03698-...
10 根据两项随机 3 期研究的结果11,12,帕博利珠单抗(抗 PD-1)于 2024 年获得美国食品药品监督管理局和中国药品审评中心批准,作为既往接受过除含 PD-1 或 PD-L1 抑制剂方案以外的全身治疗的肝细胞癌患者的二线单药疗法。 TACE embolises the vasculature of the tumour, resulting in necrosis, but previous...
PD-L1 status 0.282 0.380 Positive (vs. negative) 0.727 0.243–2.171 0.568 0.496 0.156–1.581 0.236 Unknown (vs. negative) 1.301 0.510–3.321 0.582 0.813 0.296–2.229 0.687 mLIPI score 0.002 0.026 Intermediate (vs. good) 2.341 1.179–4.647 0.015 2.436 1.160–5.114 0.019 Poor/very poor (vs. ...